Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know

The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.